Arnold & Porter's Life Sciences legal work was recognized twice at the 10thannual LMG Life Science Awards on September 8, 2022.
Life Sciences and Healthcare Regulatory partner Jeffrey Handwerker was recognized as "Regulatory Attorney of the Year: Pricing & Reimbursement." Handwerker focuses his practice on pharmaceutical pricing and investigations, government contracts, and commercial litigation involving the pharmaceutical, medical products, and biotechnology industries. He regularly advises pharmaceutical and medical technology companies, as well as represents clients in litigation matters, internal investigations, and government audits and investigations.
Arnold & Porter also was recognized with the "Impact Deal of the Year" award for its work advising Novartis on its $1 billion license agreement with BeiGene. The firm advised Novartis in an option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab in development to treat non-small cell lung cancer and a wide range of solid tumors, with up to $1 billion in upfront consideration. The Arnold & Porter team advising Novartis included co-chair of the firm's Corporate and Finance group Derek Stoldt, partner Eric Rothman, and associate Tracey Klees.